Stifel Nicolaus initiated coverage on shares of argenx (NASDAQ:ARGX) in a report released on Thursday morning, The Fly reports. The firm issued a buy rating and a $139.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. Wedbush boosted their price objective on shares of argenx from $93.00 to $114.00 and gave the company an outperform rating in a research report on Monday, June 25th. Piper Jaffray Companies reiterated an overweight rating and set a $130.00 price objective on shares of argenx in a research report on Thursday, June 7th. JMP Securities boosted their price objective on shares of argenx from $93.00 to $130.00 and gave the company a positive rating in a research report on Monday, June 18th. ValuEngine upgraded shares of argenx from a hold rating to a buy rating in a research report on Friday, June 1st. Finally, Nomura began coverage on shares of argenx in a research report on Friday, June 29th. They set a buy rating and a $161.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $125.14.

ARGX stock opened at $93.78 on Thursday. argenx has a twelve month low of $21.25 and a twelve month high of $103.00. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of -66.99 and a beta of 2.07.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Atria Investments LLC bought a new position in shares of argenx in the second quarter worth about $213,000. BB Biotech AG grew its holdings in shares of argenx by 13.2% in the second quarter. BB Biotech AG now owns 449,049 shares of the company’s stock worth $37,208,000 after purchasing an additional 52,230 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of argenx by 1.6% in the second quarter. Jennison Associates LLC now owns 332,013 shares of the company’s stock worth $27,511,000 after purchasing an additional 5,276 shares during the last quarter. Loomis Sayles & Co. L P bought a new position in shares of argenx in the first quarter worth about $13,373,000. Finally, TD Asset Management Inc. grew its holdings in shares of argenx by 8.2% in the second quarter. TD Asset Management Inc. now owns 38,832 shares of the company’s stock worth $3,218,000 after purchasing an additional 2,952 shares during the last quarter. Hedge funds and other institutional investors own 56.14% of the company’s stock.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Article: Technical Analysis

The Fly

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.